Articles

Six potential high-impact outcomes of NHS devolution for industry

6th March 2015

Six potential high-impact outcomes of NHS devolution for industryAngela McFarlane

The Conservatives, lead partners in the coalition government, have just announced a hugely significant new experiment in how health and social care is provided in the UK: The Greater Manchester... Read more

Can the rise in drug-drug interactions be halted, or is it an inevitab…

5th March 2015

Can the rise in drug-drug interactions be halted, or is it an inevitable side effect?Philip MacLaughlin

The trend towards patients taking several medications at the same time is increasing, especially with the ageing population, giving rise to a corresponding rise in the possibility of adverse reactions.... Read more

Applying marketing thinking to the clinical trial process

4th March 2015

Applying marketing thinking to the clinical trial processKen Wallace

In order to attract and retain patients for a clinical trial, clinical teams should start early on planning and implementing their marketing strategies. Ken Wallace suggests the patient recruitment questions... Read more

Clinical trials insight: paediatric trials

3rd March 2015

Clinical trials insight: paediatric trialsAlex Muntañola

pharmaphorum spoke to Alex Cvetkovich Muntañola about the current status of paediatric trials and the challenges that lie ahead.Could you give an overview of where paediatric clinical trials are in... Read more

News

Summit Therapeutics to raise funds for Duchenne and C diff drugs

5th March 2015

Summit Therapeutics to raise funds for Duchenne and C diff drugsAndrew McConaghie

UK biotech firm Summit Therapeutics is preparing a US share offer to raise funding for its research programmes.The Oxford-based company is already listed on London's AIM market, but will now... Read more

AbbVie swoops for Pharmacyclics in $21bn takeover

5th March 2015

AbbVie swoops for Pharmacyclics in $21bn takeoverAndrew McConaghie

Johnson & Johnson has missed out on acquiring its marketing partner Pharmacyclics after AbbVie snatched the company from under its nose with a $21 billion takeover.The acquisition of Pharmacyclics and... Read more

Opdivo cleared for lung cancer in record time

5th March 2015

Opdivo cleared for lung cancer in record timeStaff reporter

Bristol-Myers Squibb's Opdivo has been cleared in the US to treat lung cancer, a full three months ahead of the FDA's review deadline.The positive verdict by the agency gives PD-1... Read more

BMS keeps foot on immuno-oncology accelerator

4th March 2015

BMS keeps foot on immuno-oncology acceleratorStaff reporter

A filing for anti-PD-1 drug Opdivo in lung cancer, plus three new licensing and acquisition deals, shows Bristol-Myers Squibb (BMS) has no intention of slowing its immuno-oncology drive.The US FDA... Read more

Audio & Video

Live Tweetchat: Managing COPD in the rea…

Tweetchat-600x400a

Working in partnership, Atlantis Healthcare and pharmaphorum present a Tweetchat focussed on the real world challenges patients face in managing their COPD,... View more

Live webinar/debate - Feb 4th - COPD, co…

Join the COPD webinar/debate

 

 

COPD is a widespread, costly and largely preventable condition which affects over 300 million people worldwide and is recognised... View more

On demand webinar: The Price is Right? -…

Slide-300x200b

 

With challenges to highly priced rare disease medicines and the Cancer Drug Fund evolving again – what is next, what are the... View more

Now on demand - real world insight into …

The Diabetes Debate

 

Now available on demand (free to access) - originally broadcast on October 29th 2014.


Non-adherence to self-management regimens in diabetes is globally... View more

White Papers

Computer Gaming: The Future of Decision-…

Computer Gaming: The Future of Decision-Making for Life Sciences?

How can life science brands identify winning strategic decisions when there are so many variables to consider? One route is via 'road-testing' decisions ahead of sign-off under computer game simulated... View info

How do doctors want to engage with pharm…

How do doctors want to engage with pharma on new products?Dr Tim Ringrose

With more than 80 per cent of European doctors saying they want to stay abreast of new developments about pharmaceutical products, it is important to understand how they wish to... View info

Modelling patient behaviour to improve s…

Modelling patient behaviour to improve self-management in diabetesDr Sinéad NíMhurchadha & Jeremy Sayers

An understanding of health psychology is essential to helping patients adhere to their medication and lifestyle regimens. This report hones in on how the COM-B model of behaviour provides a... View info

"The future ain’t what it used to b…

"The future ain’t what it used to be"Paul Stuart-Kregor

Preparation is key to creating and maintaining a strong drugs pipeline. However, the statistics demonstrate that successful product commercialisation strategies are not always implemented. Products are developed for which there... View info

Further News & Articles

NICE backs Gilead's Harvoni in draft guidance

Patients in England and Wales look set to get access to Gilead Sciences' new hepatitis C virus (HCV) therapy Har... Read more

News

Sanofi's Toujeo heads latest crop of CHMP opinions

Sanofi's long-acting follow-up to blockbuster basal insulin Lantus has been recommended for approval in the EU, ... Read more

News

GSK has most to prove after $16 bn Novartis deal

The $16 billion dollar 'asset swap' deal between GlaxoSmithKline (GSK) and Novartis has been formally completed ... Read more

News

We need to talk about ChemSex: risks of Hep C and HIV are high

More gay men in the UK are presenting to clinicians with complicated issues associated with drug use and consent ... Read more

Articles

Finance could provide answer to pharma pricing conflicts

The financial sector could provide an answer to the increasingly vexed issues of very high costs for innovative ... Read more

News

Bayer sets big targets for 2015

Bayer will need a stellar performance from its growth products this year, as it is predicting a €4 billion incre... Read more

News